Paclitaxel Plus Carboplatin Is Reportedly Non-Interior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma

January 13, 2022 8:49 am

by Ariana Pelosci

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A combination regimen of paclitaxel

Read more

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7, 2022 11:18 am

by Kristi Rosa

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced

Read more

FDA Clears Amma, a Scalp-Cooling Device to Prevent Chemo-Related Hair Loss in Patients With Cancer

December 8, 2021 9:18 am

by Brielle Benyon

Amma was developed by a cancer survivor who wanted an easier — and cheaper — way for patients to preserve their hair during chemotherapy treatment.

The Food and Drug Administration (FDA) granted clearance to Amma, a scalp-cooling

Read more

AGO Score Identifies Ovarian Cancer Patients Likely to Benefit from Cytoreductive Surgery

December 6, 2021 2:29 pm

by Sucharita Mistry, PhD

Cytoreductive surgery followed by chemotherapy can prolong overall survival (OS), compared with chemotherapy alone, in certain patients with relapsed ovarian cancer, according to results from the DESKTOP III trial published in the New England Journal of Read more

Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer

November 30, 2021 12:10 pm

by Nichole Tucker

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant

Read more

FDA approves pioneering drug for ovarian cancer surgery

November 29, 2021 10:11 am

by Steve Tally

Purdue-developed imaging drug allowed surgeons to find additional cancer lesions

Left image: A drug used for fluorescent imaging during ovarian cancer surgeries, which was just approved by the FDA, lights up cancer cells “like stars against a Read more

Neoadjuvant Chemo for Advanced Ovarian Cancer Reduced Short-Term Mortality

September 30, 2021 12:00 am

By Mike Bassett

— Programs frequently using this treatment achieved these declines without compromising OS

Cancer programs that were more likely to use neoadjuvant chemotherapy to treat advanced ovarian cancer saw larger declines in short-term mortality versus programs with less … Read more

Breakthrough Therapy Designation Granted to VS-6766 Plus Defactinib for Pretreated Low-Grade Serous Ovarian Cancer

May 25, 2021 5:00 pm

A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.

By Audrey Sternberg

The combination of the RAF/MEK inhibitor, VS-6766, plus the FAK inhibitor, defactinib, … Read more

Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer

May 24, 2021 3:00 pm

By Jennifer Southall

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical OncologyRead more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

Smart Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials

April 28, 2021 7:00 pm

By Lindzi Wessel

Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer patients with solid tumors. Now, in two Read more

Carboplatin Alone Not Adequate for Ovarian Cancer in Frail Seniors

April 27, 2021 6:00 pm

Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer.

For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April

Read more

Ovarian Cancer and a New Era for Clinical Trials

April 20, 2021 9:00 am

At Clearity we are intent on bringing the future of ovarian cancer treatment to women today. It’s exciting to have the opportunity to work with other organizations who share our vision. Teckro’s goal is to make clinical trials more accessible, Read more

Tislelizumab Plus Sitravatinib Demonstrates Antitumor Activity, Maintains Safety in Platinum-Resistant Epithelial Ovarian Cancer

April 14, 2021 3:00 pm

For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.

By Kristi Rosa

For patients with recurrent platinum-resistant epithelial

Read more

Cancer Discovery Could Revive Failed Treatments for Solid Tumors

April 5, 2021 11:00 am

New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.

The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more

What to Know About Telehealth for Ovarian Cancer

April 2, 2021 1:30 am

Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more

Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

March 26, 2021 1:00 pm

Ixabepilone plus bevacizumab yielded responses in a third of patients.

By Ian Ingram

Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.

Median progression-free … Read more

HIPEC Combo Doubles PFS in Advanced Ovarian Cancer

March 26, 2021 12:00 pm

Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.

By Charles Bankhead

Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.

Median progression-free survival (PFS) doubled … Read more

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

March 22, 2021 4:00 pm

By Chase Doyle

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

March 22, 2021 3:00 pm

By Chase Doyle

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more